The enzyme arginase catalyses the divalent cation dependent hydrolysis of L-arginine to produce L-ornithine and urea. Two isoforms of arginases have been identified in mammalian (including human) cells. Moreover, some infectious pathogens (e.g. Leishmania) synthesize their own arginase. Work over the last decades has revealed that elevated arginase activity both decreases cellular availability in nitric oxide (NO) by competing with NO synthases (NOS) and increases concentration in L-ornithine, a precursor in the biosynthesis of polyamines which are important for cell differentiation and proliferation. From these data emerged the concept that selective arginase inhibitors might be a valuable strategy for treatment of various diseases associated with decreased NO and/or increased polyamines production. Consistent with this, recent research provides compelling evidence supporting the beneficial effects of arginase inhibitors in cardiovascular diseases (hypertension, ischemia reperfusion injury, atherosclerosis, diabetes mellitus), asthma, cancer, immunologically-mediated diseases or leishmaniasis. Despite active programs to identify potent arginase inhibitors, effective chemical compounds with reliable pharmacokinetics and toxicological properties are rare. The present review summarizes available data on the discovery of new arginase inhibitors from natural origin. Current knowledge on plant-derived compounds or extracts with arginase inhibitory properties as well as available data on structure-activity relationship (SAR) will be presented. Lastly, the present review will open up new prospects in order to improve the discovery of novel arginase inhibitors from natural sources.
Keywords: Arginase inhibitors, cardiovascular diseases, leishmaniasis, natural substances, polyphenols.
Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine
Current Pharmaceutical Design Cockroach Allergens: Function, Structure and Allergenicity
Protein & Peptide Letters Targeting the Histamine H4 Receptor: Future Drugs for Inflammatory Diseases
Current Organic Chemistry Immunostimulatory Oligonucleotides
Recent Patents on Inflammation & Allergy Drug Discovery IL-4 and IL-13: Their Pathological Roles in Allergic Diseases and their Potential in Developing New Therapies-Update
Medicinal Chemistry Reviews - Online (Discontinued) Prevention and Treatment of Allergic Asthma in Pregnancy: From Conventional Drugs to New Therapeutical Approaches
Current Pharmaceutical Biotechnology Mechanistic Systems Biology of Inflammatory Gene Expression in Airway Smooth Muscle as Tool for Asthma Drug Development
Current Drug Discovery Technologies Obesity in the Patient with Lung Disease
Current Respiratory Medicine Reviews Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
Current Pharmaceutical Design Schistosoma mansoni Antigens as Modulators of the Allergic Inflammatory Response in Asthma
Endocrine, Metabolic & Immune Disorders - Drug Targets Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Biomarkers in the Management of Difficult Asthma
Current Topics in Medicinal Chemistry Myeloperoxidase: The Good, the Bad, and the Ugly
Current Immunology Reviews Early Life Vitamin D Status and Lung Development
Current Respiratory Medicine Reviews Autophagy as a Molecular Target of Flavonoids Underlying their Protective Effects in Human Disease
Current Medicinal Chemistry Real-life Experience of Clinical Efficacy of Omalizumab Use in the MiddleEast: Should We Also Be Concerned About Parasites?
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) C/EBP Transcription Factors in Lung Disease
Current Respiratory Medicine Reviews Beta-2 Agonists in Asthma: Medicine or Murderer?
Current Respiratory Medicine Reviews Current Prospective of Aldose Reductase Inhibition in the Therapy of Allergic Airway Inflammation in Asthma
Current Molecular Medicine Investigation of 5-HT<sub>2A</sub> gene expression in PBMCs of patients with allergic asthma
Inflammation & Allergy - Drug Targets (Discontinued)